Showing papers on "Primary systemic amyloidosis published in 1986"
TL;DR: Using the proportional-hazards model in a stepwise multivariate fashion to evaluate the simultaneous influence of putative risk factors as of diagnosis revealed that congestive heart failure, urine light chain, hepatomegaly, and multiple myeloma were the major factors adversely affecting survival during the first year after diagnosis.
193 citations
TL;DR: Patients with typical jaw claudication with biopsy-proven primary amyloidosis were examined, and two patients were misdiagnosed initially as having temporal arteritis and polymyalgia rheumatica and were treated with corticosteroids, which resulted in significant toxicity.
73 citations
TL;DR: A 40-year-old man has slow-growing, nodular, amyloid tumors of the eyelid margin associated with recurrent intradermal hemorrhages for 18 years, and medical evaluation revealed no evidence of primary systemic amyloidsosis.
Abstract: • A 40-year-old man had slow-growing, nodular, amyloid tumors of the eyelid margin associated with recurrent intradermal hemorrhages for 18 years. Medical evaluation revealed no evidence of primary systemic amyloidosis. We suggest that amyloidosis be included in the differential diagnosis of painless, slow-growing, nodular tumors of the eyelid margin.
18 citations
10 citations
01 Jan 1986
TL;DR: One hundred one patients with primary amyloidosis were stratified in four groups on the basis of their major clinical features: 1) Nephrotic syndrome or renal insufficiency; 2) congestive heart failure; 3) peripheral neuropathy; and 4) other.
Abstract: One hundred one patients with primary amyloidosis (AL) were stratified in four groups on the basis of their major clinical features: 1) Nephrotic syndrome or renal insufficiency; 2) congestive heart failure; 3) peripheral neuropathy; and 4) other. The patients were randomized to 1) melphalan (0.15 mg/kg daily) and prednisone (0.8 mg/kg daily) for 7 days every 6 weeks, or 2) colchicine (0.6 mg twice a day). Forty-nine patients were randomized to melphalan-prednisone (M-P) therapy, while 52 were to receive colchicine (C). No important differences were found between the two groups in the history or the initial physical examination and laboratory findings. If there was progressive disease or lack of benefit from therapy, either M-P or C was added to the original therapeutic regimen. Twenty-one of the 40 patients with the nephrotic syndrome who received M-P had >50% reduction in urinary protein. Four patients died of acute nonlymphocytic leukemia. The median survival was 25 months for the M-P group and 18 months for the C group (P = 0.23). When survival was calculated from the onset of randomization to death or progression of disease, the median survival was 16 months for the M-P group and 6 months for the C group (P = 0.0001).
1 citations
TL;DR: A case of oral amyloidsosis as initial symptom of systemic primary amyloidosis is described, and extensive deposition of pale eosinophilic amorphous material is shown.
Abstract: Amyloidosis is a disease characterized by progressive irreversible deposition ofamyloid in the body.A case of oral amyloidosis as initial symptom of systemic primary amyloidosis is described. A 67 year old man, who complained of multiple hard nodules on the dorsal surface of the tongue, was first seen in the Oral Surgery clinic May, 1986, and the biopsy was carried out.Histology showed extensive deposition of pale eosinophilic amorphous material. Congo red stains were positive for amyloid and the typical apple green birefringences were noted on polarisation.Routine laboratory tests were initiated and Bence Jones protein (κ) was positive in urine. Bone marrow aspiration from sternum revealed plasmacytosis. Amyloid depositions were noted later on the face skin, hands and hard palate. Amyloid tumor of the hard palate as vaporized by CO2 LASER. Chemotherapy (Melphalan, predonine and DMSO) was carried out, but the effect was poor and the patient died of cerebral infarction Feb, 1985.